Top Page
Evaxion Biotech
(NASDAQ:EVAX)
Evaxion Biotech (EVAX) vs. SPDR S&P 500 ETF (SPY)
Evaxion Biotech Business Overview & Revenue Model
Evaxion Biotech Earnings Call Summary
Evaxion Biotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.30M | 3.34M | 73.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.30M | 3.34M | 72.89K | -571.32K | -343.45K | -105.72K |
| EBITDA | -9.23M | -9.77M | -21.40M | -22.58M | -24.17M | -16.46M |
| Net Income | -11.50M | -10.57M | -22.13M | -23.17M | -24.53M | -15.02M |
Balance Sheet | ||||||
| Total Assets | 15.19M | 12.48M | 12.89M | -58.94M | 40.16M | 11.96M |
| Cash, Cash Equivalents and Short-Term Investments | 4.58M | 5.05M | 5.58M | 13.18M | 32.17M | 5.83M |
| Total Debt | 0.00 | 10.10M | 10.87M | 2.25M | 3.69M | 20.00K |
| Total Liabilities | 15.19M | 14.14M | 17.62M | 13.72M | 7.73M | 4.93M |
| Stockholders Equity | 74.00K | -1.65M | -4.73M | -72.66M | -50.43M | 7.04M |
Cash Flow | ||||||
| Free Cash Flow | -2.01M | -12.94M | -17.78M | -26.07M | -23.29M | -12.83M |
| Operating Cash Flow | -2.01M | -12.94M | -17.69M | -25.77M | -21.93M | -12.44M |
| Investing Cash Flow | 1.00K | -3.00K | -93.00K | -268.00K | -1.33M | -393.00K |
| Financing Cash Flow | 5.26M | 13.13M | 10.69M | 7.85M | 49.80M | 8.82M |
Evaxion Biotech Technical Analysis
Evaxion Biotech Risk Analysis
Evaxion Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | 8.96M | -0.80 | 0.00% | ― | -100.00% | 49.47% | |
49 Neutral | 9.90M | -0.28 | 0.00% | ― | 0.00% | -219.97% | |
47 Neutral | $19.27M | ― | -321.37% | ― | 4455.07% | 77.31% | |
40 Underperform | 8.56M | -0.64 | 0.00% | ― | -34.07% | 23.79% | |
39 Underperform | 6.47M | -0.38 | 0.00% | ― | 0.00% | 53.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Evaxion Biotech Corporate Events
On August 27, 2025, Evaxion A/S announced its participation in several scientific and investor conferences across the US, Europe, and Asia during the latter half of 2025. This strategic engagement aims to present their data and discoveries, particularly the two-year clinical data for their personalized cancer vaccine EVX-01, and to explore potential business partnerships and scientific collaborations. The company’s presence at these conferences is expected to enhance its stakeholder engagement and industry positioning.
On August 14, 2025, Evaxion A/S announced a business update and second quarter 2025 financial results, highlighting significant achievements and strategic developments. The company reported the completion of patient treatment in its phase 2 trial for the personalized cancer vaccine EVX-01, with plans to present two-year clinical efficacy data at the ESMO Congress in October 2025. Additionally, Evaxion received a grant from the Gates Foundation to develop a new polio vaccine and expanded its R&D pipeline with a new vaccine program against Group A Streptococcus. Financially, Evaxion improved its position by converting debt into equity through an agreement with the European Investment Bank, enhancing its equity by $4.1 million. Despite a net loss of $4.8 million for the quarter, the company reported a solid cash position, sufficient to fund operations until mid-2026.
Evaxion Biotech A/S reported its financial results for the fiscal quarter ended June 30, 2025, showing a net loss of $4.831 million for the three months and $6.411 million for the six months. Despite the losses, the company experienced a positive exchange rate impact, contributing to a reduced comprehensive loss. This financial update is crucial for stakeholders as it highlights the company’s ongoing financial challenges amidst its innovative endeavors in the biotech sector.
On August 11, 2025, Evaxion A/S announced that it will provide a business update and report its second quarter 2025 financial results on August 14, 2025. The company plans to host a conference call and webcast on the same day to present the updates and results, which will be accessible to the public. This announcement is significant as it provides stakeholders with insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor confidence.
On July 25, 2025, Evaxion A/S announced that it will present two-year clinical efficacy data from its phase 2 trial of the AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 in October. The vaccine, designed for advanced melanoma, showed a 69% overall response rate and a positive correlation between the AI platform predictions and immune responses. This presentation at a prestigious oncology conference is expected to enhance Evaxion’s visibility and potentially attract new partnerships.
On July 11, 2025, Evaxion Biotech finalized a debt settlement agreement with the European Investment Bank (EIB), reducing its €7 million loan by €3.5 million. This was achieved by issuing warrants for 38,450,000 ordinary shares to EIB, which are exercisable immediately and expire in ten years. The agreement also included a registration rights agreement to facilitate the resale of these shares. This strategic financial move is expected to strengthen Evaxion’s financial position and enhance its operational flexibility, potentially impacting its market presence positively.
On July 11, 2025, Evaxion A/S finalized an agreement with the European Investment Bank (EIB) to convert €3.5 million of its €7 million loan into equity. This move enhances Evaxion’s equity by $4.1 million, reduces liabilities, simplifies the balance sheet, and improves financial flexibility and cash flow. The agreement, which involves EIB purchasing Evaxion warrants at a premium, is expected to positively impact the company’s financial management and stakeholder confidence.
On July 1, 2025, Evaxion A/S announced significant executive management changes to enhance its AI-Immunology platform’s value. Christian Kanstrup resigned as CEO, with Dr. Birgitte Rønø stepping in as interim CEO, and Thomas Schmidt was appointed as the permanent CFO. These changes aim to drive the company’s growth and strategic partnerships, positioning Evaxion for future advancements in its AI-driven vaccine development.
On June 25, 2025, Evaxion A/S announced the expansion of its R&D pipeline with a new vaccine program targeting Group A Streptococcus (GAS), named EVX-B4. This initiative underscores the significant medical and commercial potential of addressing GAS, which causes numerous infections globally. The addition of EVX-B4 aligns with Evaxion’s strategy to enhance its pipeline, supporting its partnership goals and increasing the number of assets for out-licensing.